News

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...